Synta (SNTA) Cuts Q2 Loss Y/Y, Madrigal Merger in Focus
Synta Pharmaceuticals Corp. SNTA reported a second-quarter 2016 loss of 2 cents per share, much lower than the year-ago loss of 15 cents.
With no approved product in its portfolio at the moment, the company does not generate revenues yet.
In the second quarter of 2016, research and development (R&D) expenses decreased by $16.5 million. General and administrative expenses increased 14.9% year over year to $3.6 million.
SYNTA PHARMACT Price
SYNTA PHARMACT Price | SYNTA PHARMACT Quote
Focus on Merger
In Apr 2016, Synta announced that it will be merging with a privately held company, Madrigal Pharmaceuticals, Inc., in an all-stock transaction. This combined company will focus on the development of novel small-molecule drugs addressing major unmet needs in cardiovascular-metabolic diseases and non-alcoholic steatohepatitis (NASH).
MGL-3196, which is Madrigal’s lead candidate, is phase II-ready for the treatment of NASH and heterozygous as well as homozygous familial hypercholesterolemia.
Once the proposed merger closes, Madrigal shareholders will own 64% of the combined company while Synta shareholders will own 36%. The merger is slated to close in the third quarter of 2016.
We note that Synta had earlier focused on cancer treatments but the company suffered a setback last year when it decided to terminate a phase III study (GALAXY-2) on its lead pipeline candidate ganetespib (for the second-line treatment of advanced non-small cell lung adenocarcinoma) due to futility. Thereafter, the company implemented strategic restructuring and discontinued a substantial portion of its R&D activities relating to ganetespib and its oncology pipeline.
However, the company continues to conduct limited activities with respect to ganetespib including providing support for a couple of ongoing investigator-sponsored studies in ovarian cancer (phase II – GANNET53) and sarcoma (phase I – SARC 023) – enrollment in both studies expected to be completed in 2017. Limited activities will also be continued for the candidates from its Hsp90 inhibitor drug conjugate (HDC) program, including its lead HDC candidate STA-12-8666.
Synta has decided not to pursue an investigational new drug (IND) submission for STA-12-8666 in the immediate future. However, the company is currently conducting pre-clinical studies on STA-12-8666 to support an IND submission, if it determines to pursue such a submission at some point in the future.
We expect investor focus to remain on updates from the Madrigal transaction, going forward.
Investors looking for well-ranked stocks in the health care sector can consider ANI Pharmaceuticals, Inc. ANIP, Bristol-Myers Squibb Company BMY and Innoviva, Inc. INVA. All three stocks sport a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
BRISTOL-MYERS (BMY): Free Stock Analysis Report
ANI PHARMACEUT (ANIP): Free Stock Analysis Report
INNOVIVA INC (INVA): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
